Atopic dermatitis (AD) has a big impact on quality of life. The usefulness of health-related quality of life questionnaires for children with AD in general practice, and the relationship of quality of life to disease severity, as assessed by parents and by investigators, however, is not known. This study used the Infants' Dermatitis Quality of Life Index (IDQoL) to assess quality of life in children with AD selected from general practice. Severity of AD was determined by investigators and parents using the objective SCORAD (SCORing Atopic Dermatitis), the TIS (three-item severity scale), or by an additional question on the IDQoL. A total of 66 patients (41% boys, mean age 31 months) were included. Correlations between disease severity assessed by parents and by investigators were low (R s 0.29-0.51). Correlations between IDQoL and severity assessed by investigators were also low (R s 0.08-0.36). However, correlations between IDQoL and severity according to parents were high (R s 0.67-0.73). In conclusion, disease severity and disease-related quality of life are different aspects of AD and must be taken into consideration when evaluating treatment or investigating new dermatological therapies in trials.
Atopic dermatitis (AD) is an inflammatory skin disease characterized by erythematous, papular or vesicular lesions in the acute form, and by lichenification in the chronic form. Patients experience itching, highly visible skin lesions, and psychological and social consequences (1).
The severity of AD is assessed with scoring systems such as the (objective) SCORAD (SCORing Atopic Dermatitis) and the 3-item severity scale (TIS) (2) (3) (4) . Whereas these systems are reliable measures to determine the extent and/or severity of AD, they fail to take into account the psychological effects and the impairment of quality of life (QoL) (5). Although patientbased outcome measures are important when assessing improvement, e.g. in clinical trials, the experience of patients is not often used as an outcome measure in such trials.
Several questionnaires are available to investigate QoL in patients with AD; these include the Dermatitis Family Impact (DFI) (6), which measures the impact of the disease on the whole family; the Children's Dermatology Life Quality Index (CDLQI) (7), demonstrating the impact of dermatological disorders in general on QoL; the Quality of Life in Atopic Dermatitis (QoLIAD) (8) , which can be used in adults; the Childhood Atopic Dermatitis Impact Scale (CADIS) (9); and the Infants' Dermatitis Quality of Life Index (IDQoL) (5, 10).
Of these questionnaires, the IDQoL appears to be a reliable and easy-to-use questionnaire which is specifically suited to children aged ≤ 4 years with AD.
In many countries, including the Netherlands, general practitioners (GPs) are the primary providers of care for patients with AD. However, the suitability of the IDQoL in general practice is not yet established, nor is the relationship between the IDQoL and disease severity, as determined by the patient and an objective observer.
This study therefore investigated whether the IDQoL is a reliable questionnaire to explore QoL in children with AD in general practice. Secondly, the severity of AD as determined by parents and by independent investigators, and the correlation between these two were examined. Finally, the correlation between QoL and severity of AD, as scored by patients and by investigators, was examined.
METHODS

Study population
Children (age range 0-6 years) with AD were included during a 5-month period to March 2008 . Patients with a history of AD were selected from GP's computerized files, either by diagnosis, which is coded according to the International Classification of Primary Care (ICPC) (11) or by prescribed medication coded according to the Anatomical Therapeutic Chemical (ATC) (12) classification scheme. Patients were selected using the ICPC code S87 (Atopic Dermatitis), and/or
Quality of Life Measurement and its Relationship to Disease Severity in Children with Atopic Dermatitis in General Practice
ATC codes specific for topical treatment of AD (zinc products, soft paraffin and fat products, other emollients and protectives, tars, topical corticosteroids). Further inclusion criteria were age (0-6 years), having visited the GP for AD complaints during the last 3 months, or having received a prescription for treatment of AD within the last 3 months and a diagnosis of AD according to Williams' criteria (13) . Patients were excluded: (i) if there was a chronic disease other than AD, asthma, food intolerance or allergic rhinitis; (ii) in case of psychological problems that could influence follow-up; (iii) other skin conditions that precluded proper assessment of the severity of AD; and (iv) if parent or caregiver was unable adequately to read and write Dutch.
Parents of selected children received a written invitation sent by their general practitioner. All parents provided written informed consent. The prospective study was approved by the local medical ethics review board.
Clinical scoring systems
To determine the clinical severity of AD the so-called objective SCORAD and the TIS score were used. Two investigators (MW and RvV) were trained by a paediatric dermatologist (APO) in the correct use of the objective SCORAD and the TIS.
The objective SCORAD, which was used as the gold standard, measures the extent and intensity (composed of six items: erythema, oedema/papules, effect of scratching, oozing/crust formation, lichenification and dryness) of the disease (4, 14) . The maximum score is 83 points; in case of disfiguring lesions or functional limiting lesions 10 bonus points are given.
The SCORAD items that represent acute symptoms are combined into the TIS (3, 15). In the TIS, the severity of AD is based on erythema, oedema and excoriations. The TIS is the sum of the three items, each scored on a scale from 0 to 3; therefore, the TIS score ranges from 0 to 9. Similar to the objective SCORAD, each item on TIS should be scored on the most representative lesion.
Infants' Dermatitis Quality of Life Index
The IDQoL questionnaire is a validated questionnaire that measures the impact of a child's dermatitis and was developed for use in children aged 0-4 years (5, 10). The present study examined the IDQoL in children aged 0-6 years.
The IDQoL includes 10 questions addressing symptoms and difficulties with mood, sleep (2 questions), play, family activities, mealtimes, treatments, dressing and bathing. The maximum score for each of the 10 questions is 3, resulting in a possible maximum score of 30 (higher scores reflecting greater impairment). An additional question (which is scored separately) asks the parents to assess the current severity of AD on a 4-point scale ranging from no AD (score 0) to extremely severe AD (score 4). The IDQoL assesses the AD problems during the preceding week. In the present study the validated Dutch version of the IDQoL questionnaire was used (16).
Data collection
All patients were visited twice, with a 3-week interval. At the first visit one of the parents was asked to complete the IDQoL (IDQoL 1 ). In order to determine test-retest reliability, a second IDQoL was completed 24 h later by the same parent (IDQoL 2 ) and was returned in a prepaid envelope. A 24-h period was chosen because this time is: (i) long enough not to (precisely) remember the answers to the questions; and (ii) the severity of eczema is still comparable to that at the time of the previous assessment. Two investigators independently examined the severity of AD in all children using the objective SCORAD and the TIS during the same visit, without knowing the score of the other observer. The mean of the scores of both investigators was calculated.
During the second visit, a final IDQoL (IDQoL 3 ) was completed by the same parent and the severity of AD (objective SCORAD and TIS) was again determined by two independent observers.
Statistical analyses
Spearman's rank correlation (r s ) and intraclass correlation coefficient (ICC) were used to analyse the test-retest reliability of the total IDQoL score and of each question separately (IDQoL 1 vs. IDQoL 2 ). R s was also used to analyse the correlation between the severity of AD as observed by the parents (extra question of the IDQoL) and as evaluated by the investigators (TIS or SCO-RAD). Additionally, the R s was used to determine the correlation between the total IDQoL scores and the severity of AD.
R s and ICC results above 0.75 were classified as excellent agreement and below 0.40 as poor agreement; results between 0.4 and 0.75 were regarded as fair to good (17). Statistical analyses were carried out using SPSS version 15.0 (SPSS Inc. Chicago, IL, uSA).
reSuLTS
A total of 278 patients with an age below 7 years and with a history of AD (ICPC S87) or use of medical treatment for AD were selected from the database of 45 GPs. These selected patients were invited by post to participate. Of these, 89 had self-reported complaints of AD at the time of invitation and were willing to participate. A final total of 66 patients fulfilled the inclusion criteria and were included. The reasons for exclusion were: few or no complaints of AD at the moment of inclusion (n = 12); response after completion of the inclusion period (n = 8); and no informed consent (n = 3). The mean age of the selected population was 31.3 months (range 0.5-83.5 months) and 41% were male.
Infants' Dermatitis Quality of Life Index
IDQoL 1 was completed for all patients during the first home visit. For the 66 patients, 58 parents (88%) returned the IDQoL 2 after 24 h, and for 65 of the 66 patients (98%) the IDQoL 3 was assessed during the second home visit. The mean score for IDQoL 1 was 6.64 (standard deviation (SD) 4.32, range 1-20), for IDQoL 2 was 6.43 (SD 4.33, , and the mean score for IDQoL 3 was 4.52 (SD 3.67, range 0-20) (Table I) . regarding the separate questions, the highest score was found for itching and scratching (question 1: mean 1.28, SD 0.89). The lowest scores concerned family activities (question 6: mean 0.20, SD 0.47) and problems during mealtimes (question 7: mean 0.14, SD 0.35) ( Table I) .
Test-retest reliability of the Infants' Dermatitis Quality of Life Index
There was excellent agreement between scores for IDQoL 1 and IDQoL 2 (R s = 0.89, p < 0.001). The ICC for these assessments was also excellent (ICC = 0.89). Individual items also showed a good or excellent agreement; however, questions 4 and 5 had a slightly lower correlation (Table II) .
Severity of atopic dermatitis
The mean score of disease severity as assessed by the parents was 1.89 (SD 1.0) at the first visit, 1.74 (SD 0.98) 24 h later, and 1.43 (SD 0.95) after 3 weeks. The mean severity score as determined by the TIS by the two independent observers was 2.3 (SD 1.18) at the first visit and 2.0 (SD 1.06) at the second visit, and for the objective SCOrAD it was 13.5 (SD 8.7) at the first visit and 11.9 (SD 7.8) at the second visit.
Correlation between severity of atopic dermatits according to investigators and parents
The correlation between severity of AD as observed by the parents and as observed by the investigators (objective SCOrAD and TIS) showed poor agreement for the first visit and fair agreement for the second visit (Table III) . Table III shows that the IDQoL had a good correlation with severity as observed by the parents (R s for first visit = 0.73, R s for second visit = 0.66). In contrast, QoL reported by the parents hardly correlated with severity as observed by the independent observers (R s range 0.08-0.36).
Correlation between Infants' Dermatitis Quality of Life Index and severity of atopic dermatitis
DISCUSSION
In the present study the IDQoL was found to be a reliable questionnaire to determine QoL in children (aged 0-6 years) with AD in general practice.
Many studies have demonstrated the relevance of measuring QoL in AD (5-10). The national Institute for Health and Clinical Excellence (NICE) guidelines for management of atopic eczema in children recommend that, in addition to measurement of severity of AD, some form of assessment of QoL should also be performed (18). most studies of QoL have been performed in patients visiting the dermatologist. However, in many countries, including the Netherlands, most patients with eczema are only treated by their general practitioner (15). The spectrum of severity of patients visiting the GP is different from patients who are referred to a dermatologist. This difference in severity can be demonstrated by two different studies in which the TIS is used as a scale to measure severity. The first study of Willemsen et al. (19) was performed in children visiting the GP, the second study was performed at a secondary care paediatric clinic (20) . In the first study the median TIS score was 2.1, and in the second study the median TIS score was 4.4. As quality of life is an essential ingredient of studies in atopic dermatitis, it should also be included in studies in general practice.
Whereas the IDQoL was not developed for children of 5 and 6 years of age, we nevertheless decided to use the same instrument for these children, since the disease spectrum and activities of the children are comparable and questions are also applicable for these children. In this study only 9 out of 66 children (14%) were 5 or 6 years of age and therefore the IDQoL is performed most of the time in children of the correct age category.
Similar to other studies (5, 6) the IDQoL showed good test-retest repeatability, implying that the parents completed both questionnaires in a consistent way. A considerably lower correlation was found only for questions 4 (sleep disturbance) and 5 (problems with swimming and playing). These questions may have been misunderstood by some parents or, as an alternative explanation, problems regarding these activities may have changed within 24 h.
Similar to other studies (5, 10), the IDQoL item with the highest score was itching and scratching. This is in accordance with the Dutch College of General Practitioners' guideline on AD (21) and criteria for diagnosing AD (13), where itch is considered to be the most prominent feature.
The severity of AD evaluated by the investigators showed low correlations with the severity according to the parents. This finding is important for the treatment of AD. Parents and physicians may interpret the severity of AD differently, which may lead to differences in expectations. For example, parents might expect additional treatment, whereas the physician may consider it unnecessary; this may lead to problems with the physician-patient relationship or with treatment adherence. This discrepancy regarding disease severity warrants further investigation. It is also important when assessing parameters for AD in clinical trials. In most trials the primary outcome measure is severity of AD as determined by the investigators. The patient's assessment of severity and QoL is seldom investigated. However, since these are different aspects of the disease, both parameters should be included when studying the effects of treatments (22) .
The correlations between the IDQoL and severity of AD determined by the observers (TIS scores and objective SCORAD scores) were rather low. This implies that, in our study population, the QoL in children with AD is not related to the severity of the AD as evaluated by the investigator. The severity of AD may not even influence the QoL. It is important that physicians are aware of this, because if the QoL is negatively affected it is more likely that a patient will seek a consultation. because physicians also take the viewpoint of the patient into consideration, if the QoL is negatively affected the physician might treat these patients in a more intensive way.
In conclusion, the IDQoL is a reliable questionnaire for determining QoL in children with AD presenting to the gP. However, there is a lack of correlation between the severity of the disease as assessed by parents and as assessed by observers. moreover, QoL is not correlated with severity as established by the investigators. Since interpretation of the inconvenience of AD seems to differ between parents and physicians, clinical trials should not focus solely on investigator-based outcomes. An assessment of the symptoms and QoL of the study participants should be included when investigating new treatment options in clinical trials.
The authors declaire no conflicts of interest
